Cited by 2,409Glioma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Response criteria for phase II studies of supratentorial malignant glioma.

Macdonald, D R, Cascino, T L, Schold, S C, Cairncross, J G·1990·Journal of Clinical Oncology

DOI 10.1200/jco.1990.8.7.1277

Open this paper in CoChat — free account

Abstract

We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.

Integrity signals

Registry

Crossref · 10.1200/jco.1990.8.7.1277

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 345
Self-citation
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J., & Wilson, C. B. (1977) · Journal of neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone, A., Longo, D. L., Vt, D., Ihde, D. C., Duffey, P. L., Jaffe, E. S., Solomon, D., HUBBARD, S. M., & Young, R. C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1832 · Cited by 178
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas
Chamberlain, M. C., Murovic, J. A., & Levin, V. A. (1988) · Neurology · doi:10.1212/wnl.38.9.1371 · Cited by 149
Steroid‐induced CT changes in patients with recurrent malignant glioma
Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100
Self-citation
Computerized tomography in the prognosis of malignant cerebral gliomas
Murovic, J. A., Turowski, K., Wilson, C. B., Hoshino, T., & Levin, V. A. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.6.0799 · Cited by 42
Criteria and definitions for response and relapse in children with brain tumors
Zeltzer, P. M., Friedman, H. S., Norris, D. G., & Ragab, A. H. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7+ · Cited by 35
Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour
Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33
Self-citation
The accuracy of volumetric measurement of high-grade gliomas
Chisholm, R. A., Stenning, S. P., & Hawkins, T. D. (1989) · Clinical Radiology · doi:10.1016/s0009-9260(89)80007-8 · Cited by 32

Flagged first, then by citations

Show all 11 references

Sorted by citations

Items 301–400 of 1,001

A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma
Hudes, R. S., Corn, B. W., Werner‐Wasik, M., Andrews, D. W., Rosenstock, J. G., Thoron, L., Downes, B., & Curran, W. J. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00416-7 · Cited by 157
Phase IB Study of Gene-Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma
Chiocca, E. A., Aguilar, L. K., Bell, S. D., Kaur, B., Hardcastle, J. J., Cavaliere, R., McGregor, J., Lo, S. S.-M., Ray-Chaudhuri, A., Chakravarti, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5222 · Cited by 159
The charing cross hospital experience with temozolomide in patients with gliomas
Newlands, E. S., O'Reilly, S. M., Glaser, M. G., Bower, M., Evans, H. S., Brock, C., Brampton, M., Colquhoun, I. R., Lewis, P. D., Rice-Edwards, J. M., et al. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00258-4 · Cited by 157
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
Dresemann, G. P., Weller, M., Rosenthal, M. A., Wedding, U., Wagner, W., Engel, E., Heinrich, B., Mayer‐Steinacker, R., Krarup‐Hansen, A., Fluge, Ø., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9976-3 · Cited by 156
A comparison of treatment results for recurrent malignant gliomas
Nieder, C., Grosu, A., & Molls, M. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0191 · Cited by 156
Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI
Kim, Y. H., Oh, S. W., Lim, Y. J., Park, C., Lee, S., Kang, K. W., Jung, H., & Chang, K. H. (2010) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2010.06.005 · Cited by 155
Radiation response and survival time in patients with glioblastoma multiforme
Barker, F. G., Prados, M. D., Chang, S. M., Gutin, P. H., Lamborn, K. R., Larson, D. A., Malec, M. K., McDermott, M. W., Sneed, P. K., Wara, W. M., et al. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.84.3.0442 · Cited by 155
Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects
Batchelor, T. T., Reardon, D. A., de Groot, J., Wick, W., & Weller, M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0834 · Cited by 157
Pediatric low-grade gliomas: implications of the biologic era
Packer, R. J., Pfister, S. M., Bouffet, É., Avery, R. A., Bandopadhayay, P., Bornhorst, M., Bowers, D. C., Ellison, D. W., Fangusaro, J., Foreman, N. K., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now209 · Cited by 155
One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma
Wick, W., Steinbach, J. P., Küker, W., DICHGANS, J., BAMBERG, M., & Weller, M. (2004) · Neurology · doi:10.1212/01.wnl.0000127617.89363.84 · Cited by 154
Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P
Kneifel, S., Cordier, D., Good, S., Ionescu, M.-C. S., Ghaffari, A., Höfer, S., Kretzschmar, M., Tolnay, M., Apostolidis, C., Waser, B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2820 · Cited by 153
Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)
Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L., Annenelie Bota, D., Rudnick, J., Love Sumrall, A., Zhu, J.-J., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.010 · Cited by 152
Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors
Bokstein, F., Shpigel, S., & Blumenthal, D. T. (2008) · Cancer · doi:10.1002/cncr.23401 · Cited by 152
Central nervous system gliomas
Reni, M., Mazza, E. A., Zanon, S. M., Gatta, G., & Vecht, C. J. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.021 · Cited by 158
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
Lassman, A. B., Pugh, S. L., Gilbert, M. R., Aldape, K., Geinoz, S., Beumer, J. H., Christner, S. M., Komaki, R. U., DeAngelis, L. M., Gaur, R., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov011 · Cited by 153
Improved prediction of metastasis in tongue carcinomas, combining vascular and nuclear tumor parameters
Hannen, E. J. M., van der Laak, J. A. W. M., Manni, J. J., Pahlplatz, M. M. M., Freihofer, H. P. M., Slootweg, P. J., Koole, R., & de Wilde, P. C. M. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7 · Cited by 7
A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas
Raizer, J. J., Grimm, S. A., Chamberlain, M. C., Nicholas, M. K., Chandler, J. P., Muro, K., Dubner, S., RADEMAKER, A. W., Renfrow, J. J., & Bredel, M. (2010) · Cancer · doi:10.1002/cncr.25462 · Cited by 149
Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study
Jaeckle, K. A., Hess, K. R., Yung, W. K. A., Greenberg, H. S., Fine, H. A., Schiff, D., Pollack, I. F., Kuhn, J. G., Fink, K., Mehta, M. P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.097 · Cited by 149
Bevacizumab and daily temozolomide for recurrent glioblastoma
Desjardins, A., Reardon, D. A., Sykes, A. D., Marcello, J. E., Herndon, J. E., Bailey, L., Peters, K. B., Friedman, H. S., & Vredenburgh, J. J. (2011) · Cancer · doi:10.1002/cncr.26381 · Cited by 147
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Erker, C. A., Tamrazi, B., Poussaint, T. Y., Mueller, S., Mata‐Mbemba, D., Franceschi, E., Brandes, A. A., Rao, A. U. K., Haworth, K. B., Wen, P. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30173-x · Cited by 147
Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D?
Dempsey, M. F., Condon, B. R., & Hadley, D. M. (2005) · PubMed Central · Cited by 147
Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma
Christians, A., Hartmann, C. J., Benner, A., Meyer, J., von Deimling, A., Weller, M., Wick, W., & Weiler, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033449 · Cited by 146
Imaging biomarkers for evaluating tumor response: RECIST and beyond
Ko, C., Yeh, L., Kuo, Y., & Chen, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00306-8 · Cited by 145
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Balañá, C., Ramírez, J. L., Tarón, M., Roussos, Y., Ariza, A., Ballester, R., Sarries, C., Méndez, P., Sánchez, J. J., & Rosell, R. (2003) · PubMed · Cited by 145
Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival
Ewelt, C., Göppert, M., Rapp, M., Steiger, H., Stummer, W., & Sabel, M. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0429-9 · Cited by 146
Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma
Kalpathy–Cramer, J., Gerstner, E. R., Emblem, K. E., Andronesi, O. C., & Rosen, B. R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0383 · Cited by 149
Concurrent Temozolomide and Dose-Escalated Intensity-Modulated Radiation Therapy in Newly Diagnosed Glioblastoma
Tsien, C. I., Brown, D. R., Normolle, D. P., Schipper, M. J., Piert, M., Junck, L., Heth, J., Gomez‐Hassan, D. M., Haken, R. K. T., Chenevert, T. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2073 · Cited by 144
Adjuvant dendritic cell‐based tumour vaccination for children with malignant brain tumours
Ardon, H., Vleeschouwer, S. D., Calenbergh, F. V., Claes, L., Kramm, C. M., Rutkowski, S., Wolff, J. E. A., & Gool, S. W. V. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22319 · Cited by 144
Oligodendroglioma: An Appraisal of Recent Data Pertaining to Diagnosis and Treatment
Fortin, D., Cairncross, G. J., Cairncross, G. J., Cairncross, G. J., Hammond, R. R., & Hammond, R. R. (1999) · Neurosurgery · doi:10.1097/00006123-199912000-00001 · Cited by 144
Prognostic Value of Early [18F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme
Piroth, M. D., Pinkawa, M., Holý, R., Klotz, J., Nussen, S., Stoffels, G., Coenen, H. H., Kaiser, H. J., Langen, K., & Eble, M. J. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.055 · Cited by 143
Treatment-Related Change Versus Tumor Recurrence in High-Grade Gliomas: A Diagnostic Conundrum—Use of Dynamic Susceptibility Contrast-Enhanced (DSC) Perfusion MRI
Fatterpekar, G. M., Galheigo, D., Narayana, A., Johnson, G., & Knopp, E. A. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.11.7417 · Cited by 144
Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Stupp, R., & Roila, F. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp151 · Cited by 148
Histopathological-Molecular Genetic Correlations in Referral Pathologist-Diagnosed Low-Grade “Oligodendroglioma”
Sasaki, H., Ƶlatescu, M. C., Betensky, R. A., Johnk, L., Cutone, A. N., Cairncross, J. G., & Louis, D. N. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.1.58 · Cited by 142
Self-citation
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
Han, K., Ren, M., Wick, W., Abrey, L. E., Das, A., Jin, J., & Reardon, D. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not236 · Cited by 141
O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
Brandes, A. A., Franceschi, E., Tosoni, A., Bartolini, S., Bacci, A., Agati, R., Ghimenton, C., Turazzi, S., Talacchi, A., Škrap, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop050 · Cited by 143
Radiation necrosis following treatment of high grade glioma—a review of the literature and current understanding
Siu, A., Wind, J. J., Iorgulescu, J. B., Chan, T. A.-T., Yamada, Y. J., & Sherman, J. H. (2011) · Acta Neurochirurgica · doi:10.1007/s00701-011-1228-6 · Cited by 141
Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma
Box, P. (2010) · International Journal of Medical Radiology · Cited by 140
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
Inogés, S., Tejada, S., de Cerio, A. L.-D., Pérez‐Larraya, J. G., Espinós, J., Idoate, M. A., Domínguez, P. D., de Eulate, M. R. G., Aristu, J., Bendandi, M., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1202-z · Cited by 143
‘Recurrent’ glioblastoma multiforme, when should we reoperate?
Barbagallo, G. M. V., Jenkinson, M. D., & Brodbelt, A. R. (2008) · British Journal of Neurosurgery · doi:10.1080/02688690802182256 · Cited by 146
Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series
Chamberlain, M. C. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1176-5 · Cited by 139
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas
Galldiks, N., Kracht, L., Burghaus, L., Thomas, A., Jacobs, A. H., Heiss, W., & Herholz, K. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-0002-5 · Cited by 139
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Chaskis, C., Dujardin, M., Everaert, H., Lv, S., Duerinck, J., Tynninen, O., Nupponen, N. N., Michotte, A., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0402-7 · Cited by 144
MRI perfusion in determining pseudoprogression in patients with glioblastoma
Young, R. J., Gupta, A. K., Shah, A. D., Graber, J. J., Chan, T. A.-T., Zhang, Z., Shi, W., Beal, K. P., & Omuro, A. M. P. (2012) · Clinical Imaging · doi:10.1016/j.clinimag.2012.02.016 · Cited by 138
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy
Galldiks, N., Law, I. G., Pope, W. B., Arbizu, J., & Langen, K. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.12.020 · Cited by 141
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
Yung, W. K. A., Vredenburgh, J. J., Cloughesy, T. F., Nghiemphu, P. L., Klencke, B. J., GILBERT, M. R., Reardon, D. A., & Prados, M. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq072 · Cited by 137
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
Chang, S. M., Lamborn, K. R., Malec, M. K., Larson, D. A., Wara, W. M., Sneed, P. K., Rabbitt, J. E., Page, M., Nicholas, M. K., & Prados, M. D. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.04.023 · Cited by 137
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations
Chinot, O. L., Barrié, M., Frauger, É., Dufour, H., Figarella-Branger, D. F., Palmari, J., Braguer, D., Hoang‐Xuan, K., Moktari, K., Peragut, J. C., et al. (2004) · Cancer · doi:10.1002/cncr.20224 · Cited by 136
Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
Chinot, O. L., Macdonald, D. R., Abrey, L. E., Zahlmann, G., Kerloëguen, Y., & Cloughesy, T. F. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0347-2 · Cited by 136
Self-citation
3′-Deoxy-3′- 18 F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab
von Schwarzenberg, J., Czernin, J. G., Cloughesy, T. F., Ellingson, B. M., Pope, W. B., Geist, C. L., Dahlbom, M. L., Silverman, D. H. S., Satyamurthy, N., Phelps, M. E., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.092387 · Cited by 135
A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
Wick, W., Fricke, H., Junge, K., Kobyakov, G., Martens, T., Heese, O., Wiestler, B., Schliesser, M. G., von Deimling, A., Pichler, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0951-t · Cited by 135
18 F-FDOPA PET for Differentiating Recurrent or Progressive Brain Metastatic Tumors from Late or Delayed Radiation Injury After Radiation Treatment
Lizárraga, K. J., Allen-Auerbach, M., Czernin, J. G., DeSalles, A. A. F., Yong, W. H., Phelps, M. E., & Chen, W. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.121418 · Cited by 135
Multi-Modal Glioblastoma Segmentation: Man versus Machine
Porz, N., Bauer, S., Pica, A., Schucht, P., Beck, J., Verma, R. K., Slotboom, J., Reyes, M., & Wiest, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096873 · Cited by 135
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
Norden, A. D., Drappatz, J., Muzikansky, A., David, K., Gerard, M., McNamara, M. B., Phan, P., Ross, A., Kesari, S., & Wen, P. Y. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9745-8 · Cited by 135
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Brandes, A. A., Franceschi, E., Tosoni, A., Hegi, M. E., & Stupp, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1810 · Cited by 135
RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study
Beier, C. P., Schmid, C., Gorlia, T., Kleinletzenberger, C., Beier, D., Grauer, O., Steinbrecher, A., Hirschmann, B., Brawanski, A., Dietmaier, C., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-308 · Cited by 125
Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods1
Galanis, E., Buckner, J. C., Maurer, M. J., Sykora, R., Castillo, R., Ballman, K. V., & Erickson, B. J. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-005 · Cited by 139
Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide
Glas, M., Hertler, C., Rieger, J., Wiewrodt, D., Bähr, O., Steinbach, J. P., Wick, W., Kortmann, R., Reifenberger, G., Weller, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2195 · Cited by 134
Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68 Ga-DOTATATE/-TOC uptake
Seystahl, K., Stoecklein, V. M., Schüller, U., Rushing, E. J., Nicolas, G., Schäfer, N., Ilhan, H., Pangalu, A., Weller, M., Tonn, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now060 · Cited by 133
Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics
Ellingson, B. M. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0506-0 · Cited by 132
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
Reardon, D. A., Desjardins, A., Peters, K. B., Gururangan, S., Sampson, J. H., McLendon, R. E., Herndon, J. E., Bulusu, A., Threatt, S., Friedman, A. H., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0722-2 · Cited by 132
Atypical teratoid rhabdoid tumor: improved long‐term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992–2012
Slavc, I., Chocholous, M., Leiss, U., Haberler, C., Peyrl, A., Azizi, A. A., Dieckmann, K. U., Wöehrer, A., Peters, C., Widhalm, G., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.161 · Cited by 132
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
Reardon, D. A., Dresemann, G. P., Taillibert, S., Campone, M., van den Bent, M. J., Clément, P. M., Blomquist, E., Gordower, L., Schultz, H., Raizer, J. J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605411 · Cited by 132
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
Reardon, D. A., Vredenburgh, J. J., Desjardins, A., Peters, K. B., Gururangan, S., Sampson, J. H., Marcello, J. E., Herndon, J. E., McLendon, R. E., Janney, D., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0217-6 · Cited by 132
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first‐line treatment of patients with glioblastoma multiforme
Hainsworth, J. D., Ervin, T. J., Friedman, E. K., Priego, V. M., Murphy, P. B., Clark, B. L., & Lamar, R. E. (2010) · Cancer · doi:10.1002/cncr.25275 · Cited by 131
How effective is BCNU in recurrent glioblastoma in the modern era?
Brandes, A. A., Tosoni, A., Amistà, P., Nicolardi, L., Grosso, D., Berti, F., & Ermani, M. (2004) · Neurology · doi:10.1212/01.wnl.0000140495.33615.ca · Cited by 131
Proton Beam Radiosurgery for Vestibular Schwannoma: Tumor Control and Cranial Nerve Toxicity
Weber, D. C., Chan, A. W., Bussière, M. R., Harsh, G. R., Ancukiewicz, M., Barker, F. G., Thornton, A. T., Martuza, R. L., Nadol, J. B., Chapman, P. H., et al. (2003) · Neurosurgery · doi:10.1227/01.neu.0000079369.59219.c0 · Cited by 131
Phase II Study of Short-Course Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Elderly Patients With Glioblastoma
Minniti, G. C., Lanzetta, G., Scaringi, C., Caporello, P., Salvati, M., Arcella, A., Sanctis, V. D., Giangaspero, F., & Enrici, R. M. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.06.1992 · Cited by 130
O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Schoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Hejleh, T. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.008 · Cited by 134
Aggressive Oligodendroglioma
Cairncross, J. G., Macdonald, D. R., & Ramsay, D. A. (1992) · Neurosurgery · doi:10.1097/00006123-199207000-00011 · Cited by 130
Self-citation
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
Reardon, D. A., Groves, M. D., Wen, P. Y., Nabors, B., Mikkelsen, T., Rosenfeld, S., Raizer, J. J., Barriuso, J., McLendon, R. E., Suttle, A. B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1707 · Cited by 131
Current status of PET imaging in neuro-oncology
Galldiks, N., Lohmann, P., Albert, N. L., Tonn, J. C., & Langen, K. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz010 · Cited by 129
Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results
Colombo, F., Barzon, L., Franchin, E., Pacenti, M., Pinna, V., Danieli, D., Zanusso, M., & Palù, G. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700851 · Cited by 129
The basis for current treatment recommendations for malignant gliomas
Fine, H. A. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052722 · Cited by 129
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group
Lin, N., Lee, E. Q., Aoyama, H., Barani, I. J., Baumert, B. G., Brown, P. D., Camidge, D. R., Chang, S. M., Dancey, J. E., Gaspar, L. E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70311-5 · Cited by 130
Self-citation
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group
Lin, N., Prowell, T. M., Tan, A. R., Kozak, M., Rosen, O., Amiri‐Kordestani, L., White, J. R., Sul, J., Perkins, L. M., Beal, K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.0761 · Cited by 128
The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression [see comments]
Blay, J., Bouhour, D., Carrié, C., Bouffet, É., Brunat-Mentigny, M., Philip, T. O., & Biron, P. (1995) · Blood · doi:10.1182/blood.v86.8.2922.2922 · Cited by 128
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
Gluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00840-1 · Cited by 127
l-Boronophenylalanine-Mediated Boron Neutron Capture Therapy for Malignant Glioma Progressing After External Beam Radiation Therapy: A Phase I Study
Kankaanranta, L., Seppälä, T., Koivunoro, H., Välimäki, P., Beule, A., Collan, J., Kortesniemi, M., Uusi-Simola, J., Kotiluoto, P., Auterinen, I., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.02.031 · Cited by 127
Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.
Cha, S., Knopp, E., Johnson, G., Litt, A. W., Glass, J., Gruber, M. L., Lu, S., & Zagzag, D. (2000) · PubMed Central · Cited by 127
Adjuvant combined modality therapy for malignant meningiomas
Chamberlain, M. C. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.84.5.0733 · Cited by 127
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma
Shih, K. C., Chowdhary, S. A., Rosenblatt, P., Weir, A. B., Shepard, G. C., Williams, J. T., Shastry, M., Burris, H. A., & Hainsworth, J. D. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2172-3 · Cited by 126
Successful treatment of low‐grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine
Stege, E. M. B., Kros, J. M., de Bruin, H. G., Enting, R. H., van Heuvel, I., Looijenga, L. H. J., van der Rijt, C. C. D., Smitt, P. A. E. S., & van den Bent, M. J. (2005) · Cancer · doi:10.1002/cncr.20828 · Cited by 126
Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
Wick, W., Weller, M., van den Bent, M. J., & Stupp, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9027 · Cited by 126
Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation★
Levin, V. A., Phuphanich, S., Yung, W. K. A., Forsyth, P. A., Maestro, R. F. D., Perry, J., Fuller, G. N., & Baillet, M. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9098-5 · Cited by 130
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy
Ananda, S., Nowak, A. K., Cher, L., Dowling, A., Brown, C., Simes, J., & Rosenthal, M. A. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.02.026 · Cited by 116
Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors
Peyrl, A., Chocholous, M., Kieran, M. W., Azizi, A. A., Prucker, C., Czech, T., Dieckmann, K. U., Schmook, M. T., Haberler, C., Leiss, U., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24006 · Cited by 124
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial
Schmainda, K. M., Zhang, Z., Prah, M. A., Snyder, B. S., Gilbert, M. R., Sorensen, A. G., Barboriak, D. P., & Boxerman, J. L. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou364 · Cited by 124
Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
Gerstner, E. R., Chen, P.-J., Wen, P. Y., Jain, R. K., Batchelor, T. T., & Sorensen, A. G. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop051 · Cited by 124
Stereotactic radiosurgery for metastatic brain tumors: a comprehensive review of complications
Williams, B. J., Suki, D., Fox, B. D., Pelloski, C. E., Maldaun, M. V. C., Sawaya, R. A., Lang, F. F., & Rao, G. (2009) · Journal of neurosurgery · doi:10.3171/2008.11.jns08984 · Cited by 124
Systemic high-dose intravenous methotrexate for central nervous system metastases
Lassman, A. B., Abrey, L. E., Shah, G. G., Panageas, K. S., Begemann, M., Malkin, M. G., & Raizer, J. J. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9044-6 · Cited by 124
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression
Gerstner, E. R., McNamara, M. B., Norden, A. D., LaFrankie, D. C., & Wen, P. Y. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9809-4 · Cited by 124
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy
Hagen, C., Schroeder, H. D., Hansen, S., Hagen, C., & Andersen, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0389 · Cited by 123
Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Brandes, A. A., Tosoni, A., Basso, U., Reni, M., Valduga, F., Monfardini, S., Amistà, P., Nicolardi, L., Sotti, G., & Ermani, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.181 · Cited by 123
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
IWAMOTO, F. M., Lamborn, K. R., Kuhn, J. G., Wen, P. Y., Yung, W. K. A., Gilbert, M. R., Chang, S. M., Lieberman, F. S., Prados, M. D., & Fine, H. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor017 · Cited by 122
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule
Perry, J., Rizek, P., Cashman, R. L., Morrison, M., & Morrison, T. (2008) · Cancer · doi:10.1002/cncr.23813 · Cited by 122
Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas
Piroth, M. D., Pinkawa, M., Holý, R., Klotz, J., Schaar, S., Stoffels, G., Galldiks, N., Coenen, H. H., Kaiser, H. J., Langen, K., et al. (2012) · Strahlentherapie und Onkologie · doi:10.1007/s00066-011-0060-5 · Cited by 122
O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation
Kreth, S., Thon, N., Eigenbrod, S., Lutz, J., Ledderose, C., Egensperger, R., Tonn, J. C., Kretzschmar, H. A., Hinske, L. C., & Kreth, F. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017156 · Cited by 122
Salvage therapy with single agent bevacizumab for recurrent glioblastoma
Chamberlain, M. C., & Johnston, S. K. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9957-6 · Cited by 124
Clinical trial end points for high-grade glioma: the evolving landscape
Reardon, D. A., Galanis, E., DeGroot, J. F., Cloughesy, T. F., Wefel, J. S., Lamborn, K. R., Lassman, A. B., Gilbert, M. R., Sampson, J. H., Wick, W., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq203 · Cited by 121
Self-citation
Phase II study of PX-866 in recurrent glioblastoma
Pitz, M. W., Eisenhauer, E. A., MacNeil, M. V., Thiessen, B. A., Easaw, J. C., Macdonald, D. R., Eisenstat, D. D., Kakumanu, A. S., Salim, M., Chalchal, H. I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou365 · Cited by 121
Self-citation

Authors: Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G.
Affiliations: Western University (CA)
ORCID: Cairncross, J G
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1990-07
Volume: 8
Issue: 7
Pages: 1277-1280
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1990.8.7.1277
OpenAlex: W1959628099
Cited by: 2,409
References: 11
Citations by year: 2026: 31 · 2025: 21 · 2024: 36 · 2023: 52 · 2022: 53 · 2021: 59 · 2020: 68 · 2019: 75 · 2018: 97 · 2017: 111 · 2016: 125 · 2015: 122 · 2014: 161 · 2013: 186 · 2012: 145
FWCI: 3.90
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: high-grade glioma, supratentorial glioma, response criteria, tumor size measurement, complete response, partial response, stable disease, progressive disease, steroid use, neurologic findings, patient selection, magnetic resonance imaging, computed tomography
MeSH terms: Diagnostic Errors, Drug Evaluation, Glioma, Humans, Magnetic Resonance Imaging, Medical Oncology, Tomography, X-Ray Computed, Supratentorial Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Response criteria for phase II studies of supratentorial malignant glioma.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks